These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Midtrimester pregnancy termination for fetal malformations. Use of intravaginal prostaglandin E2.
    Author: Hagar DL, Valley MT, Rayburn WF, Carey JC.
    Journal: J Reprod Med; 1997 Aug; 42(8):497-500. PubMed ID: 9284011.
    Abstract:
    OBJECTIVE: To compare outcome differences and responses to treatment in pregnancies complicated by either major fetal malformations or previous fetal death in the second trimester. STUDY DESIGN: Data were analyzed from a computerized perinatal database and individual hospital records for singleton gestations between 14 and 23 weeks undergoing labor induction with prostaglandin E2 (PGE2) suppositories (20 mg intravaginally every three to five hours). RESULTS: Between January 1993 and June 1995, 65 pregnancies underwent induction of labor for either a lethal fetal malformation (38) or death (27). As compared with the fetal death group, the malformation group required more suppositories (median 4, range 1-10, versus median 3, range 1-6; P < .05) and needed a greater total dosage (77.5 +/- 38.5 mg versus 61.8 +/- 37.8 mg, P < .05). The mean time from initiation of treatment until delivery was two hours longer in the malformation group. There were no significant differences between the two treatment groups in incidence of maternal side effects or of retained placentas requiring operative intervention. CONCLUSION: Patients who undergo second-trimester induction of labor for major fetal malformations using intravaginal PGE2 should be counseled that the dosage of the drug is greater and that labor may last longer than in pregnancies complicated by a previous fetal death. The capability to identify major fetal malformations in the middle trimester of pregnancy has increased the number of requests for late pregnancy termination. This retrospective study compared the use of prostaglandin E2 (PGE2) suppositories in 38 pregnancies undergoing induction of labor before 23 weeks of gestation after confirmation of 1 or more major fetal malformations and a control group of 27 pregnancies undergoing induction because of fetal death. Both groups were identified through a perinatal database of all pregnancies delivered at an Oklahoma City, Oklahoma, hospital in a 30-month period during 1992-94. The most frequent fetal malformations were cystic hygroma, spina bifida, hydrocephalus, and anencephaly. The median number of 20 mg PGE2 doses required was greater in the fetal malformation group (4, range 1-10) than the fetal death group (3, range 1-6). The total dosage was also greater for the malformation group (77.5 +or- 38.5 mg) than for the fetal death group (61.8 +or- 37.8 mg). Mean time until delivery was 2 hours less in the fetal death group, but the percentage of women delivering within 24 hours was similar in both groups (81.6% in the fetal malformation group and 85.2% in the fetal death group). All malformed fetuses were delivered stillborn. The frequencies of maternal side effects such as fever, vomiting, and diarrhea were somewhat greater in the fetal malformation group, presumably because of the higher dosage of PGE2. Although women undergoing second-trimester PGE2-induced labor for fetal malformations should be counseled that labor may last longer and a higher drug dosage may be required than in pregnancies complicated by fetal death, the method seems to be highly effective in both situations.
    [Abstract] [Full Text] [Related] [New Search]